PetIQ Inc (NASDAQ:PETQ) – Equities research analysts at William Blair lowered their FY2018 earnings estimates for shares of PetIQ in a research report issued to clients and investors on Wednesday, November 14th. William Blair analyst J. Andersen now forecasts that the company will earn $0.70 per share for the year, down from their previous forecast of $0.74.

PetIQ (NASDAQ:PETQ) last released its quarterly earnings data on Tuesday, November 13th. The company reported $0.47 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.25 by $0.22. PetIQ had a positive return on equity of 12.83% and a negative net margin of 0.12%. The business had revenue of $131.40 million for the quarter, compared to analysts’ expectations of $125.22 million. During the same quarter in the previous year, the business posted $0.30 EPS. PetIQ’s revenue for the quarter was up 116.8% on a year-over-year basis.

Other equities analysts have also recently issued research reports about the company. CL King initiated coverage on PetIQ in a report on Friday, September 28th. They set a “buy” rating and a $49.00 price objective on the stock. Raymond James reiterated a “buy” rating and set a $45.00 price objective (up previously from $33.00) on shares of PetIQ in a report on Wednesday, September 19th. Jefferies Financial Group reiterated a “buy” rating on shares of PetIQ in a report on Friday, August 24th. SunTrust Banks lifted their price objective on PetIQ to $40.00 and gave the company a “buy” rating in a report on Wednesday, August 15th. Finally, BidaskClub cut PetIQ from a “strong-buy” rating to a “buy” rating in a report on Thursday. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. PetIQ presently has a consensus rating of “Buy” and an average price target of $41.83.

NASDAQ:PETQ opened at $28.69 on Friday. PetIQ has a fifty-two week low of $17.56 and a fifty-two week high of $43.93. The company has a current ratio of 2.00, a quick ratio of 0.90 and a debt-to-equity ratio of 0.56. The stock has a market cap of $803.33 million, a PE ratio of 73.56, a price-to-earnings-growth ratio of 1.65 and a beta of 1.58.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PETQ. Harvest Fund Management Co. Ltd bought a new stake in PetIQ in the 3rd quarter valued at approximately $135,000. The Manufacturers Life Insurance Company lifted its stake in PetIQ by 64.0% in the 1st quarter. The Manufacturers Life Insurance Company now owns 6,838 shares of the company’s stock valued at $182,000 after acquiring an additional 2,669 shares in the last quarter. Zions Bancorporation bought a new stake in PetIQ in the 3rd quarter valued at approximately $187,000. Advisory Services Network LLC lifted its stake in PetIQ by 296.0% in the 3rd quarter. Advisory Services Network LLC now owns 4,950 shares of the company’s stock valued at $195,000 after acquiring an additional 3,700 shares in the last quarter. Finally, Engineers Gate Manager LP bought a new stake in PetIQ in the 3rd quarter valued at approximately $200,000.

In other PetIQ news, major shareholder Ecp Helios Partners Iv, L.P. sold 1,838,836 shares of the business’s stock in a transaction that occurred on Monday, October 1st. The stock was sold at an average price of $37.15, for a total value of $68,312,757.40. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Will Santana sold 713,167 shares of the business’s stock in a transaction that occurred on Monday, October 1st. The shares were sold at an average price of $37.15, for a total value of $26,494,154.05. The disclosure for this sale can be found here. Insiders sold a total of 3,023,503 shares of company stock worth $112,721,308 in the last 90 days. Company insiders own 45.26% of the company’s stock.

PetIQ Company Profile

PetIQ, Inc operates as a pet health and wellness company. It provides veterinarian services and veterinarian-grade pet products, including prescription (Rx) medications, over-the-counter (OTC) flea and tick preventatives, and health and wellness products for dogs and cats. The company offers pet prescription medications, including products for arthritis, thyroid, and diabetes and pain treatments, as well as heartworm preventatives, antibiotics, and other specialty medications; over-the-counter medications and supplies, such as flea and tick control products in various forms comprising spot on treatments, chewables, and collars; and health and wellness products consisting of specialty treats and other pet products, which include dental treats and nutritional supplements.

See Also: The risks of owning bonds

Earnings History and Estimates for PetIQ (NASDAQ:PETQ)

Receive News & Ratings for PetIQ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetIQ and related companies with MarketBeat.com's FREE daily email newsletter.